A comparison of semaglutide and tirzepatide Feature Semaglutide Tirzepatide FDA Approval Year 2017 (injection), 2020 (oral) 2022 Average Weight Loss ~1015% of body weight ~1520% of body weight Dosage Forms Weekly injection, oral tablet Weekly injection only Common Side Effects Nausea, vomiting, diarrhea, constipation Nausea, vomiting, diarrhea, constipation Frequency Weekly (injection), daily (oral) Weekly injection Cost (approximate) $900$1,200/month $1,000$1,300/month (Keep in mind that numbers are averages
French ED, Dillon K, Wu X
Enhanced tissue repair signaling in preclinical models
Given the high burden of MASLD in women and the poorer outcomes from the disease compared to men, it is a priority to clarify the impact of HRT on MASLD development and severity to give women the opportunity to make more informed decisions, potentially leading to improved health outcomes after menopause
Lab Anim (NY)
Under these conditions, overall GI adverse events were, however, only slightly less prevalent with tirzepatide (40.0% vs